Last reviewed · How we verify

Moxifloxacin HCl 0.5%

Carolina Eyecare Physicians, LLC · FDA-approved active Small molecule

Moxifloxacin HCl 0.5% is a Fluoroquinolone antibiotic Small molecule drug developed by Carolina Eyecare Physicians, LLC. It is currently FDA-approved for Bacterial conjunctivitis, Bacterial corneal ulcer, Other bacterial eye infections. Also known as: Vigamox, Moxeza, Vigamox.

Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in bacteria.

Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria. Used for Bacterial conjunctivitis, Bacterial corneal ulcer, Other bacterial ocular infections.

At a glance

Generic nameMoxifloxacin HCl 0.5%
Also known asVigamox, Moxeza, Vigamox
SponsorCarolina Eyecare Physicians, LLC
Drug classFluoroquinolone antibiotic
TargetBacterial DNA gyrase and topoisomerase IV
ModalitySmall molecule
Therapeutic areaOphthalmology / Infectious Disease
PhaseFDA-approved

Mechanism of action

Moxifloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA replication and repair. This dual inhibition prevents bacterial DNA from unwinding and replicating, leading to rapid bactericidal activity. The 0.5% ophthalmic formulation delivers high local concentrations to the eye to treat bacterial infections.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Moxifloxacin HCl 0.5%

What is Moxifloxacin HCl 0.5%?

Moxifloxacin HCl 0.5% is a Fluoroquinolone antibiotic drug developed by Carolina Eyecare Physicians, LLC, indicated for Bacterial conjunctivitis, Bacterial corneal ulcer, Other bacterial eye infections.

How does Moxifloxacin HCl 0.5% work?

Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in bacteria.

What is Moxifloxacin HCl 0.5% used for?

Moxifloxacin HCl 0.5% is indicated for Bacterial conjunctivitis, Bacterial corneal ulcer, Other bacterial eye infections.

Who makes Moxifloxacin HCl 0.5%?

Moxifloxacin HCl 0.5% is developed and marketed by Carolina Eyecare Physicians, LLC (see full Carolina Eyecare Physicians, LLC pipeline at /company/carolina-eyecare-physicians-llc).

Is Moxifloxacin HCl 0.5% also known as anything else?

Moxifloxacin HCl 0.5% is also known as Vigamox, Moxeza, Vigamox.

What drug class is Moxifloxacin HCl 0.5% in?

Moxifloxacin HCl 0.5% belongs to the Fluoroquinolone antibiotic class. See all Fluoroquinolone antibiotic drugs at /class/fluoroquinolone-antibiotic.

What development phase is Moxifloxacin HCl 0.5% in?

Moxifloxacin HCl 0.5% is FDA-approved (marketed).

What are the side effects of Moxifloxacin HCl 0.5%?

Common side effects of Moxifloxacin HCl 0.5% include Conjunctival irritation, Eye discomfort, Blurred vision, Ocular redness.

What does Moxifloxacin HCl 0.5% target?

Moxifloxacin HCl 0.5% targets Bacterial DNA gyrase and topoisomerase IV and is a Fluoroquinolone antibiotic.

Related